Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Fiduciary Alliance LLC

Fiduciary Alliance LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 8.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,906 shares of the medical research company’s stock after acquiring an additional 2,222 shares during the quarter. Fiduciary Alliance LLC’s holdings in Amgen were worth $7,534,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Parallel Advisors LLC lifted its stake in Amgen by 0.8% during the second quarter. Parallel Advisors LLC now owns 9,210 shares of the medical research company’s stock worth $2,878,000 after purchasing an additional 70 shares during the last quarter. Envestnet Asset Management Inc. increased its position in Amgen by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 1,408,785 shares of the medical research company’s stock worth $440,175,000 after buying an additional 107,134 shares during the period. Seven Mile Advisory increased its position in Amgen by 15.3% in the second quarter. Seven Mile Advisory now owns 852 shares of the medical research company’s stock worth $266,000 after buying an additional 113 shares during the period. Hanson & Doremus Investment Management increased its position in Amgen by 3.6% in the second quarter. Hanson & Doremus Investment Management now owns 1,592 shares of the medical research company’s stock worth $497,000 after buying an additional 55 shares during the period. Finally, Thompson Siegel & Walmsley LLC increased its holdings in shares of Amgen by 49.4% during the second quarter. Thompson Siegel & Walmsley LLC now owns 38,677 shares of the medical research company’s stock valued at $12,085,000 after purchasing an additional 12,784 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several recent analyst reports. UBS Group cut their price objective on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, October 31st. StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Robert W. Baird reaffirmed an “underperform” rating and set a $215.00 target price on shares of Amgen in a research note on Wednesday, September 25th. Redburn Partners lowered their target price on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $314.91.

Amgen Stock Performance

Shares of NASDAQ AMGN traded up $3.15 during midday trading on Monday, hitting $265.38. 286,763 shares of the company’s stock were exchanged, compared to its average volume of 2,643,644. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company’s 50 day moving average price is $279.10 and its 200 day moving average price is $308.66. The firm has a market capitalization of $142.65 billion, a PE ratio of 33.98, a price-to-earnings-growth ratio of 2.91 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period last year, the firm posted $4.96 EPS. As a group, analysts predict that Amgen Inc. will post 19.53 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.59%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is currently 121.90%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.